Aegerion Pharmaceuticals’ CEO Marc Beer is moving forward with his new medtech startup Renovia Inc. with more than $40 million in the bank.
From their new headquarters in Boston, Renovia is working towards improving women’s health with more technical options. The company aims to innovate diagnostic and therapeutic tools to address common medical problems like urinary incontinence, affecting an estimated 250 million across the world.
After obtaining FDA approval back in April, Renovia’s main focus is working on a new iteration of the Leva device
Beer secured investments from The Longwood Fund, an investment firm focused on healthcare. This drew in attention from investors like Ascension Ventures and Perceptive Advisors.
In a recent statement, Beer expressed his excitement with earning the interest of investors who are dedicated to improving the medical options available to women. A combination of proprietary technology and digital platforms, Beer hopes to also provide clients with vital data that can alter their treatment options to meet their individual healthcare needs.
About Marc Beer:
Marc Beer is an American executive with more than 25 years of experience developing and commercializing pharmaceutical products and biotechnology. He got his start marketing for Abbott Laboratories, then went on to sit on the Mass Life Science Board of the Commonwealth of Massachusetts and the BIO Emerging Companies Section Governing Board.
Beer founded ViaCell in 2000, a company dedicated to collecting and preserving stem cells from umbilical cords for further development. By the time the company went public in 2005, ViaCell had 300 employees. During this time, Beer also sat on Erytech Pharma’s board of directors. This led to a number of positions within Genzyme, ending with Vice President of Global Marketing where he oversaw the launch of products aimed at rare diseases.
Beer chaired the compensation committees for Good Start Genetics and Minerva Neurosciences Inc., companies where he was the founding chairman. But Beer is arguably best known for his time as CEO of Aegerion Pharmaceuticals. After taking the company public in 2010, JUXTAPID, their flagship product, received approval by the FDA. Under Beer’s leadership JUXTAPID was distributed to 36 countries.
Renovia is Beer’s most recent venture, a biotech company founded with Ramon Iglesias. MD and Yolanda Lorie
Beer is a graduate of Miami University (Ohio), where he sits on the Miami University Business Advisory Council. Formerly he was part of the Notre Dame Research and Commercialization Advisory Committee and Graduate Studies Research and Advisory Council. Learn more: https://www.slideshare.net/MarcBeer